Search

Displaying results 3931 - 3940 of 10000 in total
  1. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). … It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.

    Categories: Serotonin 5-HT4 Receptor Agonists
  2. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. … The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  3. Drug

    Bamifylline

    go.drugbank.com/drugs/DB13203
    Investigational

    Bamifylline is a selective A1 adenosine receptor antagonist.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-Ring
  4. Drug

    Topsalysin

    go.drugbank.com/drugs/DB05160
    Investigational

    Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.

  5. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types.

  6. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. … It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen.

    Synonyms: N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineCategories: Serotonin 5-HT2 Receptor Agonists
  7. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  8. Drug

    SGN-15

    go.drugbank.com/drugs/DB05818
    Investigational

    Doxorubicin is a type of anthracycline antitumor antibiotic. When it is combined with a monoclonal antibody, it forms a type of drug conjugate. Also called cBR96-doxorubicin immunoconjugate. … SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin.

  9. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). … It is being developed by Exelixis, Inc.

    Categories: Heterocyclic Compounds, 2-Ring, Phosphatidylinositol 3-Kinases, antagonists & inhibitors
  10. Drug

    Mesoridazine

    go.drugbank.com/drugs/DB00933
    ApprovedWithdrawn

    A phenothiazine antipsychotic with effects similar to chlorpromazine.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 3-RingSynonyms: 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine, 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine